Statistical approaches to evaluate the positive control drug using the hERG assay

Area of Science:

• Pharmacology
• Biostatistics
• Drug Safety

Background:

• The human ether-a-go-go-related gene (hERG) safety assay is critical for predicting drug-induced QT interval prolongation.
• Assessing hERG assay similarity between laboratories is challenging due to inconsistent methodologies and variability.
• Standardized quantitative assessment is needed for reliable drug safety evaluations.

Purpose of the Study:

• To develop and validate a statistical framework for quantitatively assessing hERG safety assay similarity.
• To address the challenges of inter-laboratory variability and lack of consensus in hERG assay methodology.
• To provide a reliable method for comparing hERG assay results between different laboratories.

Main Methods:

• Developed a statistical framework utilizing fixed margin equivalence testing.
• Applied the framework to real-world and simulated data for hERG safety assays.
• Compared assay results from sponsor laboratories with those following ICH E14 S7b Q&A Best Practice.

Main Results:

• The proposed framework successfully identified similar hERG assays between laboratories for 28 Comprehensive In Vitro Proarrhythmia Assay (CiPA) drugs.
• Equivalence testing results demonstrated strong agreement with domain expert assessments.
• The framework proved effective in quantitative assessment of hERG assay similarity.

Conclusions:

• The developed statistical framework provides a robust method for quantitative assessment of hERG assay similarity.
• This approach helps mitigate challenges posed by inter-laboratory variability in drug safety testing.
• The validated framework supports regulatory decision-making in drug development and safety assessment.